Review



anticollagen type ii mabs  (Chondrex Inc)


Bioz Verified Symbol Chondrex Inc is a verified supplier
Bioz Manufacturer Symbol Chondrex Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Chondrex Inc anticollagen type ii mabs
    Anticollagen Type Ii Mabs, supplied by Chondrex Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anticollagen type ii mabs/product/Chondrex Inc
    Average 94 stars, based on 1 article reviews
    anticollagen type ii mabs - by Bioz Stars, 2026-02
    94/100 stars

    Images



    Similar Products

    97
    Developmental Studies Hybridoma Bank mouse monoclonal anticollagen type ii antibody
    Mouse Monoclonal Anticollagen Type Ii Antibody, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anticollagen type ii antibody/product/Developmental Studies Hybridoma Bank
    Average 97 stars, based on 1 article reviews
    mouse monoclonal anticollagen type ii antibody - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    94
    Chondrex Inc anticollagen type ii mabs
    Anticollagen Type Ii Mabs, supplied by Chondrex Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anticollagen type ii mabs/product/Chondrex Inc
    Average 94 stars, based on 1 article reviews
    anticollagen type ii mabs - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    97
    Developmental Studies Hybridoma Bank primary mouse monoclonal anticollagen type ii antibody
    Primary Mouse Monoclonal Anticollagen Type Ii Antibody, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary mouse monoclonal anticollagen type ii antibody/product/Developmental Studies Hybridoma Bank
    Average 97 stars, based on 1 article reviews
    primary mouse monoclonal anticollagen type ii antibody - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    90
    Arthrogen BV anticollagen type ii (cii) monoclonal antibodies (mabs)
    Anticollagen Type Ii (Cii) Monoclonal Antibodies (Mabs), supplied by Arthrogen BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anticollagen type ii (cii) monoclonal antibodies (mabs)/product/Arthrogen BV
    Average 90 stars, based on 1 article reviews
    anticollagen type ii (cii) monoclonal antibodies (mabs) - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Arthrogen BV anticollagen type ii (cii) monoclonal antibodies (mabs; 53100, arthrogen-cia mab)
    Anticollagen Type Ii (Cii) Monoclonal Antibodies (Mabs; 53100, Arthrogen Cia Mab), supplied by Arthrogen BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anticollagen type ii (cii) monoclonal antibodies (mabs; 53100, arthrogen-cia mab)/product/Arthrogen BV
    Average 90 stars, based on 1 article reviews
    anticollagen type ii (cii) monoclonal antibodies (mabs; 53100, arthrogen-cia mab) - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    86
    Valiant Co Ltd monoclonal mouse anticollagen type ii
    Monoclonal Mouse Anticollagen Type Ii, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal mouse anticollagen type ii/product/Valiant Co Ltd
    Average 86 stars, based on 1 article reviews
    monoclonal mouse anticollagen type ii - by Bioz Stars, 2026-02
    86/100 stars
      Buy from Supplier

    95
    Chondrex Inc anticollagen type ii mab s
    Inhibition of collagen mAb-induced arthritis by small interfering RNA (siRNA) against tumor necrosis factor- α (TNF α ) . ( a ) Preventative treatment of mice with siRNA against TNFα (purple curve) but not against Luc (blue curve) in C12-200 formulation decreases arthritis score. Anti-VLA1 mAb given several hours before arthitogenic antibody mix was used as a positive control (green curve) as previously shown. Mice were treated with <t>anticollagen</t> <t>mAb's</t> at day 0, followed by lipopolysaccharide (LPS) on day 3. Mice receiving only arthitogenic antibodies are graphed in red. 0.5 mg/kg siRNA in C12-200 formulation was administered on days −3, 0, 4, and 7. All mice were scored on days 4–8 and 10. Each limb was evaluated and scored on a 0–4 scale. Results are expressed as the mean arthritic score (±SEM) of all four limbs (maximum score of 16). Groups of 10 mice per condition were used; one out of two experiments is shown, both showed similar protection. ( b ) Intensity of intracellular TNFα staining in CD11b + splenic macrophages from diseased mice at day 10. Groups of three mice were analyzed; bars represent average of the mean fluorescent intensity in the group with SEM, statistical analysis as described in the Results section. ( c ) Detection of inflammatory macrophage activity by fluorescence-mediated tomography (FMT) imaging. Arthritic mice treated with siRNAs targeted to TNFα or Luc were injected with Prosense-750, a pan-specific cathepsin substrate, and imaged by FMT on day 7. Fluorescence concentration reports on protease activity in the joint and was quantified as described in Supplementary Materials and Methods , n = 5, 2 paws per mouse were analyzed. Data are mean ± SEM. ( d ) Joint histology at 5x magnification in H&E staining correlated with images of the paws. ( e ) Representative images of macrophage activity measurement by FMT quantified in panel c . Naive and siRNA-treated animals are shown.
    Anticollagen Type Ii Mab S, supplied by Chondrex Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anticollagen type ii mab s/product/Chondrex Inc
    Average 95 stars, based on 1 article reviews
    anticollagen type ii mab s - by Bioz Stars, 2026-02
    95/100 stars
      Buy from Supplier

    96
    Developmental Studies Hybridoma Bank monoclonal anticollagen type ii
    Inhibition of collagen mAb-induced arthritis by small interfering RNA (siRNA) against tumor necrosis factor- α (TNF α ) . ( a ) Preventative treatment of mice with siRNA against TNFα (purple curve) but not against Luc (blue curve) in C12-200 formulation decreases arthritis score. Anti-VLA1 mAb given several hours before arthitogenic antibody mix was used as a positive control (green curve) as previously shown. Mice were treated with <t>anticollagen</t> <t>mAb's</t> at day 0, followed by lipopolysaccharide (LPS) on day 3. Mice receiving only arthitogenic antibodies are graphed in red. 0.5 mg/kg siRNA in C12-200 formulation was administered on days −3, 0, 4, and 7. All mice were scored on days 4–8 and 10. Each limb was evaluated and scored on a 0–4 scale. Results are expressed as the mean arthritic score (±SEM) of all four limbs (maximum score of 16). Groups of 10 mice per condition were used; one out of two experiments is shown, both showed similar protection. ( b ) Intensity of intracellular TNFα staining in CD11b + splenic macrophages from diseased mice at day 10. Groups of three mice were analyzed; bars represent average of the mean fluorescent intensity in the group with SEM, statistical analysis as described in the Results section. ( c ) Detection of inflammatory macrophage activity by fluorescence-mediated tomography (FMT) imaging. Arthritic mice treated with siRNAs targeted to TNFα or Luc were injected with Prosense-750, a pan-specific cathepsin substrate, and imaged by FMT on day 7. Fluorescence concentration reports on protease activity in the joint and was quantified as described in Supplementary Materials and Methods , n = 5, 2 paws per mouse were analyzed. Data are mean ± SEM. ( d ) Joint histology at 5x magnification in H&E staining correlated with images of the paws. ( e ) Representative images of macrophage activity measurement by FMT quantified in panel c . Naive and siRNA-treated animals are shown.
    Monoclonal Anticollagen Type Ii, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal anticollagen type ii/product/Developmental Studies Hybridoma Bank
    Average 96 stars, based on 1 article reviews
    monoclonal anticollagen type ii - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    97
    Developmental Studies Hybridoma Bank monoclonal anticollagen type ii igg1
    Inhibition of collagen mAb-induced arthritis by small interfering RNA (siRNA) against tumor necrosis factor- α (TNF α ) . ( a ) Preventative treatment of mice with siRNA against TNFα (purple curve) but not against Luc (blue curve) in C12-200 formulation decreases arthritis score. Anti-VLA1 mAb given several hours before arthitogenic antibody mix was used as a positive control (green curve) as previously shown. Mice were treated with <t>anticollagen</t> <t>mAb's</t> at day 0, followed by lipopolysaccharide (LPS) on day 3. Mice receiving only arthitogenic antibodies are graphed in red. 0.5 mg/kg siRNA in C12-200 formulation was administered on days −3, 0, 4, and 7. All mice were scored on days 4–8 and 10. Each limb was evaluated and scored on a 0–4 scale. Results are expressed as the mean arthritic score (±SEM) of all four limbs (maximum score of 16). Groups of 10 mice per condition were used; one out of two experiments is shown, both showed similar protection. ( b ) Intensity of intracellular TNFα staining in CD11b + splenic macrophages from diseased mice at day 10. Groups of three mice were analyzed; bars represent average of the mean fluorescent intensity in the group with SEM, statistical analysis as described in the Results section. ( c ) Detection of inflammatory macrophage activity by fluorescence-mediated tomography (FMT) imaging. Arthritic mice treated with siRNAs targeted to TNFα or Luc were injected with Prosense-750, a pan-specific cathepsin substrate, and imaged by FMT on day 7. Fluorescence concentration reports on protease activity in the joint and was quantified as described in Supplementary Materials and Methods , n = 5, 2 paws per mouse were analyzed. Data are mean ± SEM. ( d ) Joint histology at 5x magnification in H&E staining correlated with images of the paws. ( e ) Representative images of macrophage activity measurement by FMT quantified in panel c . Naive and siRNA-treated animals are shown.
    Monoclonal Anticollagen Type Ii Igg1, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal anticollagen type ii igg1/product/Developmental Studies Hybridoma Bank
    Average 97 stars, based on 1 article reviews
    monoclonal anticollagen type ii igg1 - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    Image Search Results


    Inhibition of collagen mAb-induced arthritis by small interfering RNA (siRNA) against tumor necrosis factor- α (TNF α ) . ( a ) Preventative treatment of mice with siRNA against TNFα (purple curve) but not against Luc (blue curve) in C12-200 formulation decreases arthritis score. Anti-VLA1 mAb given several hours before arthitogenic antibody mix was used as a positive control (green curve) as previously shown. Mice were treated with anticollagen mAb's at day 0, followed by lipopolysaccharide (LPS) on day 3. Mice receiving only arthitogenic antibodies are graphed in red. 0.5 mg/kg siRNA in C12-200 formulation was administered on days −3, 0, 4, and 7. All mice were scored on days 4–8 and 10. Each limb was evaluated and scored on a 0–4 scale. Results are expressed as the mean arthritic score (±SEM) of all four limbs (maximum score of 16). Groups of 10 mice per condition were used; one out of two experiments is shown, both showed similar protection. ( b ) Intensity of intracellular TNFα staining in CD11b + splenic macrophages from diseased mice at day 10. Groups of three mice were analyzed; bars represent average of the mean fluorescent intensity in the group with SEM, statistical analysis as described in the Results section. ( c ) Detection of inflammatory macrophage activity by fluorescence-mediated tomography (FMT) imaging. Arthritic mice treated with siRNAs targeted to TNFα or Luc were injected with Prosense-750, a pan-specific cathepsin substrate, and imaged by FMT on day 7. Fluorescence concentration reports on protease activity in the joint and was quantified as described in Supplementary Materials and Methods , n = 5, 2 paws per mouse were analyzed. Data are mean ± SEM. ( d ) Joint histology at 5x magnification in H&E staining correlated with images of the paws. ( e ) Representative images of macrophage activity measurement by FMT quantified in panel c . Naive and siRNA-treated animals are shown.

    Journal: Molecular therapy. Nucleic acids

    Article Title: Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells

    doi: 10.1038/mtna.2011.3

    Figure Lengend Snippet: Inhibition of collagen mAb-induced arthritis by small interfering RNA (siRNA) against tumor necrosis factor- α (TNF α ) . ( a ) Preventative treatment of mice with siRNA against TNFα (purple curve) but not against Luc (blue curve) in C12-200 formulation decreases arthritis score. Anti-VLA1 mAb given several hours before arthitogenic antibody mix was used as a positive control (green curve) as previously shown. Mice were treated with anticollagen mAb's at day 0, followed by lipopolysaccharide (LPS) on day 3. Mice receiving only arthitogenic antibodies are graphed in red. 0.5 mg/kg siRNA in C12-200 formulation was administered on days −3, 0, 4, and 7. All mice were scored on days 4–8 and 10. Each limb was evaluated and scored on a 0–4 scale. Results are expressed as the mean arthritic score (±SEM) of all four limbs (maximum score of 16). Groups of 10 mice per condition were used; one out of two experiments is shown, both showed similar protection. ( b ) Intensity of intracellular TNFα staining in CD11b + splenic macrophages from diseased mice at day 10. Groups of three mice were analyzed; bars represent average of the mean fluorescent intensity in the group with SEM, statistical analysis as described in the Results section. ( c ) Detection of inflammatory macrophage activity by fluorescence-mediated tomography (FMT) imaging. Arthritic mice treated with siRNAs targeted to TNFα or Luc were injected with Prosense-750, a pan-specific cathepsin substrate, and imaged by FMT on day 7. Fluorescence concentration reports on protease activity in the joint and was quantified as described in Supplementary Materials and Methods , n = 5, 2 paws per mouse were analyzed. Data are mean ± SEM. ( d ) Joint histology at 5x magnification in H&E staining correlated with images of the paws. ( e ) Representative images of macrophage activity measurement by FMT quantified in panel c . Naive and siRNA-treated animals are shown.

    Article Snippet: Arthrogen-collagen–induced arthritis antibody kits were purchased from Chondrex LLC (Redmond, WA), and arthritis was induced using an established protocol., Groups of 10 BALB/c mice (CRL) were injected intraperitoneally with a cocktail of five anticollagen type II mAb's (0.75 mg/animal total, Chondrex, catalog #53100) on day 0, followed by intraperitoneal injection of 25 µg lipopolysaccharide on day 3.

    Techniques: Inhibition, Small Interfering RNA, Positive Control, Staining, Activity Assay, Fluorescence, Tomography, Imaging, Injection, Concentration Assay